A Controlled Trial to Investigate the Efficacy and Safety of Frovatriptan to Prevent Menstrual Migraine
A Controlled Trial to Investigate the Efficacy and Safety of Frovatriptan to Prevent Menstrual Migraine
Although the predictability of an MRM headache attack lends itself to preventative treatment,
 there are currently no drugs specifically indicated for the prevention of MM. Such
 preventative therapies might be administered either short term (during the time around the
 period otherwise known as the peri-menstrual period or PMP) or continuously throughout the
 menstrual cycle.

 Frovatriptan has been developed for the management of migraine and is already licensed for
 use as an acute treatment for this condition. Previous well controlled clinical trials have
 highlighted the potential of frovatriptan as a short-term preventative medication for MM.
 This clinical trial was meant to further explore this indication for frovatriptan in an
 expanded population.
See above
Inclusion Criteria:

 -  Pre-menopausal females diagnosed as suffering from MRM aged 15 years and over, that
 fit the criteria for 'difficult to treat'